WO2022053486A1 - Utilisation de cannabidivarine dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques - Google Patents

Utilisation de cannabidivarine dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques Download PDF

Info

Publication number
WO2022053486A1
WO2022053486A1 PCT/EP2021/074661 EP2021074661W WO2022053486A1 WO 2022053486 A1 WO2022053486 A1 WO 2022053486A1 EP 2021074661 W EP2021074661 W EP 2021074661W WO 2022053486 A1 WO2022053486 A1 WO 2022053486A1
Authority
WO
WIPO (PCT)
Prior art keywords
cbdv
seizures
preparation
motor
use according
Prior art date
Application number
PCT/EP2021/074661
Other languages
English (en)
Inventor
Kevin James CRAIG
John Anthony LAWSON
Original Assignee
GW Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Research Limited filed Critical GW Research Limited
Priority to MX2023002837A priority Critical patent/MX2023002837A/es
Priority to US18/044,941 priority patent/US20230346809A1/en
Priority to JP2023515815A priority patent/JP2023540614A/ja
Priority to CN202180062304.9A priority patent/CN116234580A/zh
Priority to EP21769152.6A priority patent/EP4210685A1/fr
Priority to CA3191266A priority patent/CA3191266A1/fr
Priority to KR1020237012089A priority patent/KR20230066417A/ko
Priority to AU2021341452A priority patent/AU2021341452A1/en
Publication of WO2022053486A1 publication Critical patent/WO2022053486A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Definitions

  • the present invention relates to the use of cannabidivarin (CBDV) for the treatment of seizures associated with rare epilepsy syndromes.
  • CBDV cannabidivarin
  • the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with Rett syndrome.
  • the types of seizures include focal motor seizures with impairment, focal non-motor seizures with impairment, generalised motor seizures, generalised non-motor seizures, unknown onset motor seizures, and non-motor seizures.
  • the dose of CBDV is between 2.5 mg/kg/day to 10 mg/kg/day.
  • the CBDV used is in the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 1.5% (w/w).
  • the CBDV used is in the form of a botanically derived purified CBDV which comprises greater than or equal to 95% (w/w) CBDV and less than or equal to 5% (w/w) other cannabinoids, wherein the less than or equal to 5% (w/w) other cannabinoids comprise the cannabinoids tetrahydrocannabinol (THC); tetrahydrocannabivarin (THCV); cannabidiol-C1 (CBD-C1); cannabidiol (CBD); cannabidivarin acid (CBDVA) and cannabidiol-C4 (CBD-C4).
  • THC cannabinoids tetrahydrocannabinol
  • THCV tetrahydrocannabivarin
  • CBDCV cannabidiol-C1
  • CBD cannabidiol
  • CBDVA cannabidivarin acid
  • CBD-C4 cannabidiol-C4
  • the CBDV may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form.
  • Epilepsy occurs in approximately 1% of the population worldwide, (Thurman et al., 2011) of which 70% are able to adequately control their symptoms with the available existing anti-epileptic drugs (AED). However, 30% of this patient group, (Eadie et al., 2012), are unable to obtain seizure freedom from the AED that are available and as such are termed as suffering from intractable or “treatment-resistant epilepsy” (TRE).
  • TRE treatment-resistant epilepsy
  • Intractable or treatment-resistant epilepsy was defined in 2009 by the International League against Epilepsy (I LAE) as “failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom” (Kwan et al., 2009).
  • Childhood epilepsy is a relatively common neurological disorder in children and young adults with a prevalence of approximately 700 per 100,000. This is twice the number of epileptic adults per population.
  • the main symptom of epilepsy is repeated seizures.
  • Clinical observations and electroencephalography (EEG) tests are conducted and the type(s) of seizures are classified according to the ILEA classification.
  • Generalized seizures where the seizure arises within and rapidly engages bilaterally distributed networks, can be split into six subtypes: tonic-clonic (grand mal) seizures; absence (petit mal) seizures; clonic seizures; tonic seizures; atonic seizures and myoclonic seizures.
  • Focal (partial) seizures where the seizure originates within networks limited to only one hemisphere, are also split into sub-categories.
  • the seizure is characterized according to one or more features of the seizure, including aura, motor, autonomic and awareness I responsiveness.
  • a seizure begins as a localized seizure and rapidly evolves to be distributed within bilateral networks this seizure is known as a bilateral convulsive seizure, which is the proposed terminology to replace secondary generalized seizures (generalized seizures that have evolved from focal seizures and are no longer remain localized).
  • focal seizures with impairment Focal seizures where the subject’s awareness I responsiveness is altered are referred to as focal seizures with impairment and focal seizures where the awareness or responsiveness of the subject is not impaired are referred to as focal seizures without impairment.
  • Rett syndrome is a brain disorder that occurs almost exclusively in girls. After birth, girls with Rett syndrome have 6 to 18 months of apparently normal development before developing severe problems with language and communication, learning, coordination, and other brain functions. [0015] Early in childhood, affected girls lose purposeful use of their hands and begin making repeated hand wringing, washing, or clapping motions. They tend to grow more slowly than other children and about three-quarters have a small head size (microcephaly).
  • MECP2 methyl CpG binding protein 2
  • the MECP2 gene contains instructions for the synthesis of a protein called methyl cytosine binding protein 2 (MeCP2), which is needed for brain development and acts as one of the many biochemical switches that can either increase gene expression or tell other genes when to turn off and stop producing their own unique proteins.
  • MeCP2 methyl cytosine binding protein 2
  • CBD Cannabidiol
  • CBDV Cannabidivarin
  • GB 2487183 discloses use of CBDV in models in hippocampal brain slices, rat Pentylenetetrazole (PTZ) model of seizures, and rat Pilocarpine model of epilepsy.
  • PTZ Pentylenetetrazole
  • rat Pilocarpine model of epilepsy rat Pentylenetetrazole
  • Amada et al. (2013) 4 further describes the use of CBDV in a PTZ model but without any mention of Rett Syndrome.
  • Hill et al. (2013) 5 discloses a study investigating the anticonvulsant profiles of cannabis-derived botanical drug substances (BDSs). BDS used contained 47 to 58% CBDV. Again there is no mention of Rett Syndrome.
  • An earlier paper Hill et al. in 2012 6 demonstrated that CBDV alone in fact did not have any effect on pilocarpine- induced seizures.
  • Huizenga et al. (2019) 7 carried out a systematic evaluation of CBDV against multiple seizure models in postnatal day (P) 10 and 20 animals. It was found that CBDV did not suppress seizures in the metl1yl-6, 7-dinlethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM) and maximal electroshock models in P10 animals.
  • DMCM 7-dinlethoxy-4-ethyl-beta-carboline-3-carboxylate
  • GB 2569961 discloses a non-oil based oral pharmaceutical formulation comprising a cannabinoid, which may be a CBDV formulation.
  • a cannabinoid which may be a CBDV formulation.
  • WO 2017/178807 relates to the use of CBDV in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Rett Syndrome.
  • a MeCP2 KO mouse model of Rett Syndrome was used, which evaluates the effect on motor alterations and cognitive deficits.
  • CBDV was found to reduce the decrease in bodyweight and survival and also improved general condition and symptoms of mobility and breathing. The impact on seizures associated with Rett Syndrome was not studied.
  • CBDV cannabidivarin
  • the seizures associated with Rett syndrome are focal motor seizures with impairment, focal non-motor seizures with impairment, generalised motor seizures, generalised non-motor seizures, unknown onset motor seizures, and non-motor seizures.
  • the CBDV preparation comprises greater than 95% (w/w) CBDV and not more than 1.5% (w/w) tetrahydrocannabinol (THC).
  • the CBDV preparation comprises greater than or equal to 95% (w/w) CBDV and less than or equal to 5% (w/w) other cannabinoids, wherein the less than or equal to 5% (w/w) other cannabinoids comprise the cannabinoids tetrahydrocannabinol (THC); tetrahydrocannabivarin (THCV); cannabidiol-C1 (CBD-C1); cannabidiol (CBD); cannabidivarin acid (CBDVA) and cannabidiol-C4 (CBD-C4).
  • THC cannabinoids tetrahydrocannabinol
  • THCV tetrahydrocannabivarin
  • CBDCV cannabidiol-C1
  • CBD cannabidio
  • the CBDV preparation is used in combination with one or more concomitant anti-epileptic drugs (AED).
  • AED concomitant anti-epileptic drugs
  • the one or more AED is selected from the group consisting of: primidone, carbamazepine, zonegran, phenobarbitone, lamotrigine, levetiracetam, sodium valproate and clobazam.
  • the CBDV is present is isolated from cannabis plant material.
  • the CBDV is present as a synthetic preparation.
  • the dose of CBDV is greater than 2.5 mg/kg/day. More preferably the dose of CBDV is 10 mg/kg/day. More preferably the dose of CBDV is 20 mg/kg/day. More preferably the dose of CBDV is 25 mg/kg/day. More preferably the dose of CBDV is 50 mg/kg/day.
  • a method of treating seizures associated with Rett syndrome comprising administering a cannabidivarin (CBDV) preparation to the subject in need thereof.
  • CBDV cannabidivarin
  • cannabinoids Over 100 different cannabinoids have been identified, see for example, Handbook of Cannabis, Roger Pertwee, Chapter 1, pages 3 to 15. These cannabinoids can be split into different groups as follows: Phytocannabinoids; Endocannabinoids and Synthetic cannabinoids (which may be novel cannabinoids or synthetically produced phytocannabinoids or endocannabinoids).
  • phytocannabinoids are cannabinoids that originate from nature and can be found in the cannabis plant. The phytocannabinoids can be isolated from plants to produce a highly purified extract or can be reproduced synthetically.
  • “Highly purified cannabinoids” are defined as cannabinoids that have been extracted from the cannabis plant and purified to the extent that other cannabinoids and non-cannabinoid components that are co-extracted with the cannabinoids have been removed, such that the highly purified cannabinoid is greater than or equal to 95% (w/w) pure.
  • Synthetic cannabinoids are compounds that have a cannabinoid or cannabinoid-like structure and are manufactured using chemical means rather than by the plant.
  • Phytocannabinoids can be obtained as either the neutral (decarboxylated form) or the carboxylic acid form depending on the method used to extract the cannabinoids. For example, it is known that heating the carboxylic acid form will cause most of the carboxylic acid form to decarboxylate into the neutral form.
  • Treatment-resistant epilepsy (TRE) or “intractable epilepsy” is defined as per the I LAE guidance of 2009 as epilepsy that is not adequately controlled by trials of one or more AED.
  • Tonic seizures can be generalised onset, affecting both sides of the brain, or they can be focal onset, starting in just one side of the brain. If a tonic seizure starts in both sides of the brain, all muscles tighten and the subject’s body goes stiff. If standing, they may fall to the floor, their neck may extend, eyes open wide and roll upwards, whilst their arms may raise upwards and legs stretch or contract. If a tonic seizure starts in one side of the brain muscles tighten in just one area of the body. Tonic seizures usually last less than one minute.
  • “Clonic seizures” are characterised by sustained rhythmical jerking. During a clonic seizure, jerking of the body or parts of the body are the main symptom. They can begin in one area or affect both sides of the brain. Whilst such seizures are rare, they cannot be stopped by restraining the person.
  • Tonic-clonic seizures consist of two phases: the tonic phase and the clonic phase. In the tonic phase the body becomes entire rigid, and in the clonic phase there is uncontrolled jerking. Tonic-clonic seizures may or may not be preceded by an aura, and are often followed by headache, confusion, and sleep. They may last mere seconds or continue for several minutes. These seizures are also known as a grand mal seizure.
  • Atonic seizures occur when a person suddenly loses muscle tone so their head or body may go limp. They are also known as drop attacks. In some children, only their head drops suddenly. They can begin in one area or side of the brain (focal onset) or both sides of the brain (generalized onset).
  • “Myoclonic seizures” are characterised by a ‘muscle jerk’. Myoclonic seizures are brief but can happen in clusters (many happening close together in time) and often happen shortly after waking. In myoclonic seizures the person is conscious, but they are classified as generalised seizures. [0052] “Absence seizures” also may be called "petit mal” seizures. These types of seizure cause a loss of awareness for a short time. They mainly affect children although can happen at any age. During an absence seizure, a person may: stare blankly into space; look like they're "daydreaming"; flutter their eyes; make slight jerking movements of their body or limbs. The seizures usually only last up to 15 seconds and may occur several times a day.
  • “Focal Seizures” are defined as seizures which originate within networks limited to only one hemisphere. What happens during the seizure depends on where in the brain the seizure happens and what that part of the brain normally does.
  • “Focal seizures without impairment” are seizures which originate within networks limited to only one hemisphere where the awareness or responsiveness of the subject is not impaired.
  • “Focal seizure with impairment” usually start in a small area of the temporal lobe or frontal lobe of the brain and involve other areas of the brain within the same hemisphere that affect alertness and awareness. Most subjects experience automatisms during a focal seizure with impaired consciousness.
  • “Focal seizure with secondary generalisation” start in a limited area on one side of the brain and spread to involve both sides. This is different from a generalized onset seizure, which starts on both sides of the brain.
  • “Epileptic spasm”, “spasms”, “infantile spasm”, “juvenile spasm” or “West syndrome” is defined as sudden flexion, extension or mixed flexion-extension of proximal and truncal muscles, lasting 1-2 seconds. Spasms typically occur in a series, usually on wakening. Subtle forms may occur with only chin movement, grimacing, or head nodding. Spasms may be bilaterally symmetric, asymmetric, or unilateral, depending on whether they are generalised onset or focal onset.
  • “Generalized Seizures” affect both sides of the brain or groups of cells on both sides of the brain at the same time. This term includes seizures types like tonic-clonic, absence, or atonic.
  • Unknown onset seizures occur when the beginning of the seizure is not known.
  • a seizure could also be called an unknown onset if it is not witnessed or seen by anyone, for example when seizures happen at night or in a person who lives alone.
  • Seizures can also be described by whether motor symptoms occur i.e. whether movements happen during a seizure, known as a “motor seizure.” When no motor symptoms happen, it can be called a “non-motor seizure.”
  • motor seizures may include clonic, atonic, tonic, myoclonic seizures, or epileptic spasms. There may also be automatisms or repeated automatic movements, like clapping or rubbing of hands, lipsmacking or chewing, or running. Non-motor symptoms may include changes in sensation, emotions, thinking or cognition, autonomic functions, or lack of movement (behavior arrest).
  • motor seizures usually consist of tonic-clonic seizures.
  • Other types also include clonic, atonic, tonic, myoclonic seizures or epileptic spasms.
  • Nonmotor symptoms are usually absence seizures. Absence seizures can also have myoclonus that can affect a specific part of the body or just the eyelids.
  • Non-motor seizures usually include a behavior arrest.
  • Plant material harvested from the Cannabis sativa L. plant was subjected to liquid carbon dioxide extraction, to produce a botanical extract containing CBDV in addition to other cannabinoids and non-cannabinoid components.
  • the extract was then further purified by a solvent crystallization method to yield botanically derived purified CBDV.
  • the crystallization process specifically removed other cannabinoids and plant components to yield greater than 95% (w/w) CBDV.
  • Both the botanical starting material and the botanical extract may be controlled by specifications.
  • An exemplary CBDV preparation of botanically derived purified CBDV is described in Table 1.1 below. In some embodiments, the isomeric content for each cannabinoid may also be specified. Table 1.1 : Specification of an exemplary botanically derived purified CBDV preparation i.NMT- Not more than
  • the purity of the botanically derived purified CBDV preparation was greater than or equal to 95%.
  • the botanically derived purified CBDV includes THC and other cannabinoids, e.g., CBD, CBDVA, THCV, CBD-C1 , and CBD-C4.
  • Distinct chemotypes of the Cannabis sativa L. plant have been produced to maximize the output of the specific chemical constituents, the cannabinoids. Certain chemovars produce predominantly CBDV. Only the (-)-trans isomer of CBDV is believed to occur naturally. During purification, the stereochemistry of CBDV is not affected.
  • High CBDV chemovars were grown, harvested, dried, baled and stored in a dry room until required.
  • the botanical raw material (BRM) was finely chopped using an Apex mill fitted with a 1 mm screen. The milled BRM was stored in a freezer prior to extraction.
  • the BDS produced using the methodology above was dispersed in C5-C12 straight chain or branched alkane.
  • the mixture was manually agitated to break up any lumps and the sealed container then placed in a freezer for approximately 48 hours.
  • the crystals were isolated via vacuum filtration, washed with aliquots of cold C5-C12 straight chain or branched alkane, and dried under a vacuum of ⁇ 10mb at a temperature of 60°C until dry.
  • the botanically derived purified CBDV preparation was stored in a freezer at -20°C in a pharmaceutical grade stainless steel container, with FDA food grade approved silicone seal and clamps.
  • CBDV preparation could be produced synthetically by producing a composition with duplicate components.
  • Example 1 describes the use of a botanically derived purified CBDV in an open label, phase I trial to investigate the clinical efficacy and safety of purified pharmaceutical cannabidivarin formulation (CBDV) in the treatment of patients diagnosed with Rett syndrome.
  • CBDV cannabidivarin formulation
  • Subjects were required to be on one or more AEDs at stable doses for a minimum of 4 weeks prior to baseline. Subjects had to have been diagnosed with intractable epilepsy: failed adequate trial of two, or more, standard anticonvulsants, and four or more quantifiable seizures less than 8 weeks prior to screening, and two or more quantifiable seizures in prospective baseline phase.
  • Seizure frequency, intensity, and duration were recorded by caregivers in a diary during a baseline period of at least 28 days. Changes in seizure frequency relative to baseline were calculated after at least 2 weeks and at defined timepoints of treatment.
  • Patients may be defined as responders if they had more than 50% reduction in seizure frequency compared to baseline.
  • the percent change of seizure frequency for the end of the treatment period was calculated as follows:
  • % reduction ((monthly seizure frequency Baseline) - (monthly seizure frequency End)) x100 seizure frequency (monthly seizure frequency Baseline)
  • Table 1 Patient demographics, seizure type and concomitant medication
  • PRI primidone
  • CAR carbamazepine
  • ZON zonegran
  • PHE phenobarbitone
  • LAM lamotrigine
  • LEV levetiracetam
  • VAL sodium valproate
  • CLO clobazam
  • Tables 2A-2E illustrate the seizure frequency for each patient.
  • Table 2A Seizure frequency data for Patient 1
  • Patient 1 was treated for 14 months and experienced a 52.5% reduction in seizures over the treatment period.
  • CBDV was effective in reducing the frequency of all seizure types: focal motor seizures with impairment, focal non-motor seizures with impairment, generalised motor seizures, generalised non-motor seizures, unknown onset motor seizures, non-motor seizures and other types.
  • CBDV was able to significantly reduce the number of seizures associated with Rett syndrome.
  • the treatment is of significant benefit in this difficult to treat epilepsy syndrome given the high responder rate experienced in four of the five patients.
  • this study signifies the use of CBDV for treatment of seizures associated with Rett syndrome.
  • Seizure types include focal motor seizures with impairment, focal non-motor seizures with impairment, generalised motor seizures, generalised non-motor seizures, unknown onset motor seizures, and non-motor seizures for which seizure frequency rates decreased by significant rates, by up to 98%.
  • CBDV canbidivarin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation de cannabidivarine (CBDV) pour le traitement de crises associées à des syndromes épileptiques rares. En particulier, les crises associées à des syndromes épileptiques rares qui sont traitées sont celles qui sont rencontrées chez des patients chez lesquels a été diagnostiqué un syndrome de Rett. Dans un autre mode de réalisation, les types de crises comprennent des crises motrices focales avec une déficience, des crises non motrices focales avec une déficience, des crises motrices généralisées, des crises non motrices généralisées, des crises motrices à déclenchement inconnu et des crises non motrices. De préférence, la dose de CBDV est comprise entre 2,5 mg/kg/jour et 10 mg/kg/jour.
PCT/EP2021/074661 2020-09-10 2021-09-08 Utilisation de cannabidivarine dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques WO2022053486A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MX2023002837A MX2023002837A (es) 2020-09-10 2021-09-08 Uso de cannabidivarina en el tratamiento de crisis convulsivas asociadas a sindromes de epilepsia raros relacionados con anomalias geneticas.
US18/044,941 US20230346809A1 (en) 2020-09-10 2021-09-08 Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
JP2023515815A JP2023540614A (ja) 2020-09-10 2021-09-08 遺伝子異常に関係する稀なてんかん症候群に関連する発作の治療におけるカンナビジバリンの使用
CN202180062304.9A CN116234580A (zh) 2020-09-10 2021-09-08 次大麻二酚在治疗与同遗传异常有关的罕见癫痫综合征相关的癫痫发作中的用途
EP21769152.6A EP4210685A1 (fr) 2020-09-10 2021-09-08 Utilisation de cannabidivarine dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques
CA3191266A CA3191266A1 (fr) 2020-09-10 2021-09-08 Utilisation de cannabidivarine dans le traitement de crises associees a des syndromes epileptiques rares lies a des anomalies genetiques
KR1020237012089A KR20230066417A (ko) 2020-09-10 2021-09-08 유전적 이상과 관련된 희귀 뇌전증 증후군과 연관된 발작의 치료에 있어서 칸나비디바린의 용도
AU2021341452A AU2021341452A1 (en) 2020-09-10 2021-09-08 Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2014250.1A GB202014250D0 (en) 2020-09-10 2020-09-10 Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2014250.1 2020-09-10

Publications (1)

Publication Number Publication Date
WO2022053486A1 true WO2022053486A1 (fr) 2022-03-17

Family

ID=73149611

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/074661 WO2022053486A1 (fr) 2020-09-10 2021-09-08 Utilisation de cannabidivarine dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques

Country Status (10)

Country Link
US (1) US20230346809A1 (fr)
EP (1) EP4210685A1 (fr)
JP (1) JP2023540614A (fr)
KR (1) KR20230066417A (fr)
CN (1) CN116234580A (fr)
AU (1) AU2021341452A1 (fr)
CA (1) CA3191266A1 (fr)
GB (2) GB202014250D0 (fr)
MX (1) MX2023002837A (fr)
WO (1) WO2022053486A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487183A (en) 2011-01-04 2012-07-18 Gw Pharma Ltd Cannabidivarin (CBDV) for use in the treatment of epilepsy
WO2017178807A1 (fr) 2016-04-11 2017-10-19 GW Research Limited Utilisation de cannabidivarine dans le traitement du trouble du spectre autistique, de troubles associés et de la schizophrénie
GB2569961A (en) 2018-01-03 2019-07-10 Gw Res Ltd Pharmaceutical
WO2021079148A1 (fr) * 2019-10-25 2021-04-29 GW Research Limited Préparations de cannabidivarine destinées à être utilisées comme médicament

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487183A (en) 2011-01-04 2012-07-18 Gw Pharma Ltd Cannabidivarin (CBDV) for use in the treatment of epilepsy
WO2017178807A1 (fr) 2016-04-11 2017-10-19 GW Research Limited Utilisation de cannabidivarine dans le traitement du trouble du spectre autistique, de troubles associés et de la schizophrénie
GB2569961A (en) 2018-01-03 2019-07-10 Gw Res Ltd Pharmaceutical
WO2019135075A1 (fr) * 2018-01-03 2019-07-11 GW Research Limited Composition pharmaceutique comprenant un cannabinoïde
WO2021079148A1 (fr) * 2019-10-25 2021-04-29 GW Research Limited Préparations de cannabidivarine destinées à être utilisées comme médicament

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AMADA ET AL.: "Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression", PEERJ, vol. 1, 2013, pages 1 - 18, XP055644803, DOI: 10.7717/peerj.214
ANONYMOUS: "Public summary of opinion on orphan designation: Cannabidivarin for the treatment of Rett syndrome", EUROPEAN MEDICINES AGENCY, 5 January 2018 (2018-01-05), pages 1 - 4, XP055845500, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/17/1921-public-summary-opinion-orphan-designation-cannabidivarin-treatment-rett-syndrome_en.pdf> [retrieved on 20210928] *
HILL ET AL.: "Cannabidivarin is anticonvulsant in mouse and rat", BRITISH JOURNAL OF PHARMACOLOGY, vol. 167, 2012, pages 1629 - 1642, XP055644795, DOI: 10.1111/j.1476-5381.2012.02207.x
HILL ET AL.: "Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism", BRITISH JOURNAL OF PHARMACOLOGY, vol. 170, 2013, pages 679 - 692, XP055241333, DOI: 10.1111/bph.12321
HUIZENGA ET AL.: "Preclinical safety and efficacy of cannabidivarin for early life seizures", NEUROPHARMACOLOGY, vol. 148, 2019, pages 189 - 198, XP085640807, DOI: 10.1016/j.neuropharm.2019.01.002
T D M HILL ET AL: "Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB 1 receptor-independent mechanism", BRITISH JOURNAL OF PHARMACOLOGY, vol. 170, no. 3, 17 September 2013 (2013-09-17), UK, pages 679 - 692, XP055241333, ISSN: 0007-1188, DOI: 10.1111/bph.12321 *
TRISTAN T. SANDS ET AL: "Long term safety, tolerability, and efficacy of cannabidiol in children with refractory epilepsy: Results from an expanded access program in the US", CNS DRUGS, vol. 33, 1 January 2019 (2019-01-01), pages 47 - 60, XP055852436 *
VIGLI ET AL.: "Chronic Treatment With the Phytocannabinoid Cannabidivarin (CBDV) Rescues Behavioural Alterations and Brain Atrophy in a Mouse Model of Rett Syndrome", NEUROPHARMACOLOGY, 2018
ZAMBERLETTI ET AL.: "Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice", JOURNAL OF PSYCHOPHARMACOLOGY, 2019

Also Published As

Publication number Publication date
US20230346809A1 (en) 2023-11-02
AU2021341452A1 (en) 2023-03-23
EP4210685A1 (fr) 2023-07-19
GB202112440D0 (en) 2021-10-13
KR20230066417A (ko) 2023-05-15
MX2023002837A (es) 2023-03-17
CN116234580A (zh) 2023-06-06
GB202014250D0 (en) 2020-10-28
CA3191266A1 (fr) 2022-03-17
JP2023540614A (ja) 2023-09-25
GB2599492A (en) 2022-04-06

Similar Documents

Publication Publication Date Title
EP3972575A1 (fr) Utilisation de cannabidiol dans le traitement de spasmes épileptiques
EP4182024A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des mutations dans le gène syngap1
AU2021341452A1 (en) Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
WO2022017937A1 (fr) Utilisation du cannabidiol dans le traitement de crises associées au syndrome de rett
GB2597281A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
WO2022017944A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à une dégénérescence cérébrale bilatérale
WO2022017945A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques
WO2022017935A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies structurales du cerveau
WO2022017957A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à un accident vasculaire cérébral ou à une hémorragie cérébrale
WO2022017930A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées au syndrome de jeavon
WO2022017915A1 (fr) Cannabidiol destiné à être utilisé dans le traitement de crises associées à des lésions cérébrales
WO2022017947A1 (fr) Utilisation du cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques
WO2022017936A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes d&#39;épilepsies rares liés à des anomalies structurales du cerveau
WO2022017929A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à la lissencéphalie
EP4181902A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques
WO2022017958A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées au syndrome du bébé secoué
WO2022123236A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques chez des patients prenant du brivaracétam
GB2597278A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017917A1 (fr) Cannabidiol destiné à être utilisé dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies structurales du cerveau
GB2597305A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017961A1 (fr) Utilisation du cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21769152

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3191266

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2023515815

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021341452

Country of ref document: AU

Date of ref document: 20210908

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20237012089

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021769152

Country of ref document: EP

Effective date: 20230411